Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE-3: TTFields + Paclitaxel in Recurrent Ovarian Cancer
NCT03940196Phase 3Completed
- Sponsor
- NovoCure
- Start
- Mar 2019
- Primary completion
- May 2023
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer (2 arms), sponsored by NovoCure. Primary endpoint: Overall Survival at 4 years. Started Mar 2019; status: completed.
02
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03940196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940196.